Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seltorexant respiratory safety in OSA
NCT03796026Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of seltorexant in Insomnia and major depressive disorder (MDD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Apnea-Hypopnea Index at Day 4. Started Jan 2019; status: completed.
02
Drugs
seltorexant
03
Conditions
Insomniamajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03796026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03796026.